@grandslam... Indeed it is a common outcome. OTOH, this company has always been different. There is no reason in the world why it should still exist, after decades of floundering. And yet someone -- now someone with reasonably deep pockets -- continues to invest. And this after spending a ton of money to right the ship with the SEC and prepare for an IPO ...only to have it fail at the altar twice this year.
It's just too weird. The rational part of me says that it's a lost cause. But the part of me that owns a boatload of shares can't let go completely. In the end, I think it just comes down to the fact that Dr. Musick believes in the product and the science behind it. As he told me once, it's his life's work. My sense is that he wants to see it through very badly. I suspect that he wants to be the one who finally put cell-based treatments on the mainstream map. And he won't take no for an answer. And he's not young. I think he has seen some remarkable results overseas, which don't count with the FDA except as basic safety data. But the results are the results. And I think he wants to do these domestic clinical trials very badly, to prove a point. Just one person's conjecture.
But, again, the rational side of me finds it difficult to see any near term path to eventual ROI. It's going to take a major surprise, some sort of breakthrough. And I'm fresh out of that kind of optimism at this point.
